Xencor Stock Forecast, Price & News

Xencor (NASDAQ:XNCR) Frequently Asked Questions

Is Xencor a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 sell rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xencor stock.
View analyst ratings for Xencor or view top-rated stocks.

How has Xencor's stock price been impacted by COVID-19 (Coronavirus)?

Xencor's stock was trading at $28.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XNCR shares have increased by 24.4% and is now trading at $34.97.
View which stocks have been most impacted by COVID-19.

When is Xencor's next earnings date?

Xencor is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Xencor.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.06. The biopharmaceutical company had revenue of $19.68 million for the quarter, compared to analyst estimates of $17.63 million. Xencor had a negative net margin of 2.53% and a negative trailing twelve-month return on equity of 0.68%. During the same quarter in the prior year, the business posted ($0.22) EPS.
View Xencor's earnings history.

What price target have analysts set for XNCR?

9 equities research analysts have issued 12 month target prices for Xencor's shares. Their forecasts range from $34.00 to $71.00. On average, they anticipate Xencor's share price to reach $54.13 in the next year. This suggests a possible upside of 54.8% from the stock's current price.
View analysts' price targets for Xencor or view top-rated stocks among Wall Street analysts.

Who are Xencor's key executives?

Xencor's management team includes the following people:

• Bassil I. Dahiyat, President, Chief Executive Officer & Director
• John J. Kuch, Chief Financial Officer & Senior Vice President
• John R. Desjarlais, Chief Scientific Officer & Senior VP-Research
• Allen Yang, Chief Medical Officer & Senior Vice President
• Celia Eckert, Secretary, General Counsel & Vice President

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor CEO Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among Xencor's employees.

Who are some of Xencor's key competitors?

Some companies that are related to Xencor include Organon & Co. (OGN), Biohaven Pharmaceutical (BHVN), Maravai LifeSciences (MRVI), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Mirati Therapeutics (MRTX), Legend Biotech (LEGN), Arena Pharmaceuticals (ARNA), Arrowhead Pharmaceuticals (ARWR), Sarepta Therapeutics (SRPT), Perrigo (PRGO), HUTCHMED (HCM), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE) and Ionis Pharmaceuticals (IONS).
View all of XNCR's competitors.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by a number of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.07%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own Xencor stock include Allen Yang, Bassil I Dahiyat, Celia Eckert, John J Kuch, John S Stafford III and Ronin Capital, Llc.
View institutional ownership trends for Xencor.

Which institutional investors are selling Xencor stock?

XNCR stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., and State of Alaska Department of Revenue. Company insiders that have sold Xencor company stock in the last year include Allen Yang, Bassil I Dahiyat, Celia Eckert, and John J Kuch.
View insider buying and selling activity for Xencor or view top insider-selling stocks.

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $34.97.

How much money does Xencor make?

Xencor has a market capitalization of $2.05 billion and generates $122.69 million in revenue each year. The biopharmaceutical company earns $-69.33 million in net income (profit) each year or ($0.10) on an earnings per share basis.

How many employees does Xencor have?

Xencor employs 202 workers across the globe.

What is Xencor's official website?

The official website for Xencor is www.xencor.com.

Where are Xencor's headquarters?

Xencor is headquartered at 111 WEST LEMON AVENUE, MONROVIA CA, 91016.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at [email protected], or via fax at 626-305-0350.